PRVA · Insider Trading
Privia Health Group, Inc. Common Stock
Every open-market purchase and sale reported by PRVA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Opella Finley Ernest | Director | A | +6,350 | — |
| 2026-07-13 | David Mountcastle | EVP & Chief Financial Officer | Sell | −21,275 | −$588.68K |
| 2026-07-09 | David Mountcastle | EVP & Chief Financial Officer | Sell | −600 | −$16.54K |
| 2026-07-07 | David Mountcastle | EVP & Chief Financial Officer | Sell | −24,734 | −$680.18K |
| 2026-07-07 | Matthew Shawn Morris | Director | MIXED | — | −$2.85M |
| 2026-07-02 | Matthew Shawn Morris | Director | MIXED | — | −$3.30M |
| 2026-05-22 | Jaewon Ryu | Director | A | +8,463 | — |
| 2026-05-22 | Nancy G Cocozza | Director | A | +8,463 | — |
| 2026-05-22 | Lance Berberian | Director | A | +8,463 | — |
| 2026-05-22 | Thomas A McCarthy | Director | A | +8,463 | — |
| 2026-05-22 | David P King | Director | A | +8,463 | — |
| 2026-05-22 | Francis S Soistman Jr | Director | A | +8,463 | — |
| 2026-05-22 | Matthew Shawn Morris | Director | A | +8,463 | — |
| 2026-05-22 | Pamela O Kimmet | Director | A | +8,463 | — |
| 2026-05-13 | Parth Mehrotra | Chief Executive Officer | Sell | −121,086 | −$2.73M |
| 2026-05-13 | David Mountcastle | EVP & Chief Financial Officer | Sell | −3,385 | −$76.50K |
| 2026-05-05 | Matthew Shawn Morris | Director | MIXED | — | −$416.39K |
| 2026-05-05 | David Mountcastle | EVP & Chief Financial Officer | MIXED | — | −$193.07K |
| 2026-04-06 | David Mountcastle | EVP & Chief Financial Officer | Sell | −5,566 | −$116.05K |
| 2026-03-18 | David Mountcastle | EVP & Chief Financial Officer | Sell | −6,391 | −$141.31K |
| 2026-03-18 | Parth Mehrotra | Chief Executive Officer | Sell | −26,509 | −$586.11K |
| 2026-03-16 | Parth Mehrotra | Chief Executive Officer | Sell | −53,992 | −$1.17M |
| 2026-03-16 | David Mountcastle | EVP & Chief Financial Officer | Sell | −13,018 | −$282.60K |
| 2026-03-12 | David Mountcastle | EVP & Chief Financial Officer | A | +77,919 | — |
| 2026-03-12 | Parth Mehrotra | Chief Executive Officer | MIXED | +292,149 | −$479.11K |
| 2026-03-12 | Edward C Fargis | EVP & General Counsel | A | +28,268 | — |
| 2026-03-10 | David Mountcastle | EVP & Chief Financial Officer | Sell | −11,006 | −$252.98K |
| 2026-03-10 | Parth Mehrotra | Chief Executive Officer | Sell | −63,439 | −$1.46M |
| 2026-03-10 | Edward C Fargis | EVP & General Counsel | Sell | −9,343 | −$214.76K |
| 2026-03-02 | Matthew Shawn Morris | Director | MIXED | — | −$559.70K |
| 2026-03-02 | David Mountcastle | EVP & Chief Financial Officer | MIXED | — | −$300.72K |
| 2025-12-16 | Matthew Shawn Morris | Director | MIXED | — | −$314.02K |
| 2025-12-16 | David Mountcastle | EVP & Chief Financial Officer | MIXED | — | −$550.12K |
| 2025-07-17 | Lance Berberian | Director | A | +7,668 | — |
| 2025-05-23 | Nancy G Cocozza | Director | A | +8,396 | — |
| 2025-05-23 | Jaewon Ryu | Director | A | +8,396 | — |
| 2025-05-23 | Patricia Anne Maryland | Director | A | +8,396 | — |
| 2025-05-23 | David P King | Director | A | +8,396 | — |
| 2025-05-23 | Thomas A McCarthy | Director | A | +8,396 | — |
| 2025-05-23 | David S Wichmann | Director | A | +8,396 | — |
| 2025-05-23 | Matthew Shawn Morris | Director | A | +8,396 | — |
| 2025-05-23 | Pamela O Kimmet | Director | A | +8,396 | — |
| 2025-05-14 | Parth Mehrotra | Chief Executive Officer | Sell | −29,682 | −$734.28K |
| 2025-05-14 | David Mountcastle | EVP & Chief Financial Officer | Sell | −3,322 | −$83.02K |
| 2025-05-02 | Matthew Shawn Morris | Director | Sell | −10,309 | −$240.51K |
| 2025-05-02 | Parth Mehrotra | Chief Executive Officer | Sell | −32,465 | −$753.07K |
| 2025-05-02 | David Mountcastle | EVP & Chief Financial Officer | Sell | −3,445 | −$80.37K |
| 2025-04-03 | David Mountcastle | EVP & Chief Financial Officer | Sell | −5,630 | −$126.00K |
| 2025-03-14 | Parth Mehrotra | Chief Executive Officer | Sell | −10,514 | −$252.65K |
| 2025-03-12 | David Mountcastle | EVP & Chief Financial Officer | Sell | −5,851 | −$141.66K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David S Wichmann | Director | 1,341,049 | $30.40M |
| Parth Mehrotra | Chief Executive Officer | 583,475 | $13.23M |
| David Mountcastle | EVP & Chief Financial Officer | 173,548 | $3.93M |
| Matthew Shawn Morris | Director | 142,860 | $3.24M |
| Edward C Fargis | EVP & General Counsel | 111,979 | $2.54M |
| Thomas A McCarthy | Director | 69,470 | $1.57M |
| David P King | Director | 50,775 | $1.15M |
| Jaewon Ryu | Director | 47,110 | $1.07M |
| Nancy G Cocozza | Director | 42,814 | $970.59K |
| Patricia Anne Maryland | Director | 42,312 | $959.21K |
| Pamela O Kimmet | Director | 34,172 | $774.68K |
| Lance Berberian | Director | 16,131 | $365.69K |
| Francis S Soistman Jr | Director | 8,463 | $191.86K |
| Opella Finley Ernest | Director | 6,350 | $143.95K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PRVA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.